Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 13, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 110 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 13, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 110 mg".